Endometriosis - Pipeline Review, H1 2014 @ http://www.researchmoz.us/endometriosis-pipeline-review-h1-2014-report.html This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

1. Endometriosis - Pipeline Review, H1 2014
Endometriosis - Pipeline Review, H1 2014
Summary
Global Markets Directs, Endometriosis - Pipeline Review, H1 2014, provides an overview of the Endometriosiss therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Endometriosis, complete with comparative analysis at various stages,
therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured
news and press releases. It also reviews key players involved in the therapeutic development for Endometriosis and special features on late-stage and discontinued
projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built
using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and
featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug
profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the
latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that
the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by
identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Endometriosis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration
details & other developmental activities
- The report reviews key players involved in the therapeutics development for Endometriosis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Endometriosis products under development by companies and universities/research institutes based on information derived from company and
industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Endometriosis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Endometriosis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Endometriosis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
table Of Contents 2
list Of Tables 8
list Of Figures 9
introduction 10
global Markets Direct Report Coverage 10
endometriosis Overview 11
therapeutics Development 12
pipeline Products For Endometriosis - Overview 12
pipeline Products For Endometriosis - Comparative Analysis 13
endometriosis - Therapeutics Under Development By Companies 14
endometriosis - Therapeutics Under Investigation By Universities/institutes 17
endometriosis - Pipeline Products Glance 19
late Stage Products 19
clinical Stage Products 20
Endometriosis - Pipeline Review, H1 2014

2. early Stage Products 21
unknown Stage Products 22
endometriosis - Products Under Development By Companies 23
endometriosis - Products Under Investigation By Universities/institutes 25
endometriosis - Companies Involved In Therapeutics Development 26
euroscreen S.a. 26
takeda Pharmaceutical Company Limited 27
neurocrine Biosciences, Inc. 28
astellas Pharma Inc. 29
kissei Pharmaceutical Co., Ltd. 30
sk Chemicals Co., Ltd. 31
bayer Ag 32
addex Therapeutics 33
evotec Ag 34
valirx Plc 35
repros Therapeutics Inc. 36
dongkook Pharmaceutical Co., Ltd. 37
camurus Ab 38
lipicard Technologies Limited 39
orphagen Pharmaceuticals, Inc. 40
peptron, Inc. 41
preglem Sa 42
endoceutics, Inc. 43
isifer Ab 44
elexopharm Gmbh 45
apavadis Biotechnologies Srl 46
abbvie Inc. 47
balonco Gmbh 48
forendo Pharma Oy 49
endometriosis - Therapeutics Assessment 50
assessment By Monotherapy Products 50
assessment By Combination Products 51
assessment By Target 52
assessment By Mechanism Of Action 55
assessment By Route Of Administration 58
assessment By Molecule Type 60
drug Profiles 62
elagolix Sodium - Drug Profile 62
product Description 62
mechanism Of Action 62
r&d Progress 62
leuprolide Acetate Sr - Drug Profile 64
product Description 64
mechanism Of Action 64
r&d Progress 64
degarelix - Drug Profile 65
product Description 65
mechanism Of Action 65
r&d Progress 65
(acolbifene + Dhea + Gnrh Agonist) - Drug Profile 66
product Description 66
mechanism Of Action 66
r&d Progress 66
relugolix - Drug Profile 67
product Description 67
mechanism Of Action 67
r&d Progress 67
telapristone Acetate - Drug Profile 68
product Description 68
mechanism Of Action 68
r&d Progress 68
pgl-2001 - Drug Profile 70
product Description 70
mechanism Of Action 70
r&d Progress 70
klh-2109 - Drug Profile 72
product Description 72
mechanism Of Action 72
Endometriosis - Pipeline Review, H1 2014

3. r&d Progress 72
asp-1707 - Drug Profile 73
product Description 73
mechanism Of Action 73
r&d Progress 73
endole - Drug Profile 74
product Description 74
mechanism Of Action 74
r&d Progress 74
bentamapimod - Drug Profile 75
product Description 75
mechanism Of Action 75
r&d Progress 75
teverelix - Drug Profile 76
product Description 76
mechanism Of Action 76
r&d Progress 76
bay-1026153 - Drug Profile 78
product Description 78
mechanism Of Action 78
r&d Progress 78
adx-68692 - Drug Profile 79
product Description 79
mechanism Of Action 79
r&d Progress 79
esn-364 - Drug Profile 80
product Description 80
mechanism Of Action 80
r&d Progress 80
val-201 - Drug Profile 81
product Description 81
mechanism Of Action 81
r&d Progress 81
leuprolide Acetate - Drug Profile 82
product Description 82
mechanism Of Action 82
r&d Progress 82
gnrh Antagonists - Drug Profile 83
product Description 83
mechanism Of Action 83
r&d Progress 83
small Molecule To Inhibit 17 Beta-hsd1 For Endometriosis And Breast Cancer - Drug Profile 84
product Description 84
mechanism Of Action 84
r&d Progress 84
hsd Research Program - Drug Profile 85
product Description 85
mechanism Of Action 85
r&d Progress 85
small Molecules For Endometriosis - Drug Profile 86
product Description 86
mechanism Of Action 86
r&d Progress 86
nce-403 - Drug Profile 87
product Description 87
mechanism Of Action 87
r&d Progress 87
aminopeptidase A Program - Drug Profile 88
product Description 88
mechanism Of Action 88
r&d Progress 88
meta Program - Drug Profile 89
product Description 89
mechanism Of Action 89
r&d Progress 89
drugs To Inhibit Gnrh Receptor For Dermatology, Hormonal Disorders, Non Malignant Disorders, Oncology And Women Health - Drug Profile 90
product Description 90
mechanism Of Action 90
Endometriosis - Pipeline Review, H1 2014

4. r&d Progress 90
eve-104 - Drug Profile 91
product Description 91
mechanism Of Action 91
r&d Progress 91
ec-304 - Drug Profile 92
product Description 92
mechanism Of Action 92
r&d Progress 92
triptorelin Pamoate Biosimilar - Drug Profile 93
product Description 93
mechanism Of Action 93
r&d Progress 93
goserelin Biosimilar - Drug Profile 94
product Description 94
mechanism Of Action 94
r&d Progress 94
lt-6121 - Drug Profile 95
product Description 95
mechanism Of Action 95
r&d Progress 95
kisspeptin Peptide Antagonists - Drug Profile 96
product Description 96
mechanism Of Action 96
r&d Progress 96
small Molecule To Inhibit 17hsd1 For Endometriosis - Drug Profile 97
product Description 97
mechanism Of Action 97
r&d Progress 97
recombinant Pigment Epithelium Derived Factor - Drug Profile 98
product Description 98
mechanism Of Action 98
r&d Progress 98
vpe-001 - Drug Profile 99
product Description 99
mechanism Of Action 99
r&d Progress 99
small Molecule To Inhibit 17beta-hydroxysteroid Dehydrogenase Type1 For Endometriosis And Estrogen Dependent Cancers - Drug Profile 100
product Description 100
mechanism Of Action 100
r&d Progress 100
drug Targeting Rerg For Endometriosis - Drug Profile 102
product Description 102
mechanism Of Action 102
r&d Progress 102
small Molecules To Inhibit Prostanoid Ep2 And Ep4 Receptors For Endometriosis - Drug Profile 103
product Description 103
mechanism Of Action 103
r&d Progress 103
steroidogenic Factor-1 Antagonists - Drug Profile 104
product Description 104
mechanism Of Action 104
r&d Progress 104
program For Women Health - Drug Profile 105
product Description 105
mechanism Of Action 105
r&d Progress 105
emmprin-conjugates - Drug Profile 106
product Description 106
mechanism Of Action 106
r&d Progress 106
drugs Inhibiting Axl/gas6 Signaling - Drug Profile 107
product Description 107
mechanism Of Action 107
r&d Progress 107
drug To Inhibit C-jun For Endometriosis - Drug Profile 108
product Description 108
mechanism Of Action 108
Endometriosis - Pipeline Review, H1 2014

5. r&d Progress 108
endometriosis - Recent Pipeline Updates 109
endometriosis - Dormant Projects 122
endometriosis - Discontinued Products 123
endometriosis - Product Development Milestones 124
featured News & Press Releases 124
oct 03, 2013: Valirx Files Phase Ib/dose Escalation Study For Val201 124
aug 29, 2013: Neurocrine Biosciences Announces The Start Of Second Phase Iii Study Of Elagolix In Endometriosis 124
apr 25, 2013: Valirx Receives Australian Patent For Val201 125
nov 13, 2012: Repros Presents Proellex Clinical Updates At Lazard Capital Markets 9th Annual Healthcare Conference 125
oct 08, 2012: Repros Therapeutics's Proellex Receives Fda Acceptance For Reclassification Of Clinical Hold Status 126
aug 27, 2012: Fda Provides Recommendations For Phase Ii Protocol For Repros' Proellex In Treatment Of Endometriosis 127
jul 30, 2012: Fda Schedules Meeting With Repros To Discuss Phase Ii Protocol For Proellex For Treatment Of Endometriosis 127
jul 16, 2012: Fda Provides Guidance To Repros For Conducting Phase Ii Study Of Proellex In Treatment Of Endometriosis 128
jun 05, 2012: Abbott Initiates Phase Iii Study Of Elagolix In Patients With Endometriosis 128
may 29, 2012: Repros Provides Updates On Proellex Clinical Programs Status 128
appendix 130
methodology 130
coverage 130
secondary Research 130
primary Research 130
expert Panel Validation 130
contact Us 131
disclaimer 131
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Endometriosis - Pipeline Review, H1 2014